«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年05期

页码:

390-394398

栏目:

基础医学

出版日期:

2018-09-20

文章信息/Info

Title:

Influence of l-carnitine on the antitumor effects of docetaxel in NCI-H520 cells

作者:

钱兴运; 郎娟娟; 陶若琳; 吴春暖; 王 晨

天津医科大学肿瘤医院药学部，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津300060

Author(s):

QIAN Xing-yun; LANG Juan-juan;  TAO Ruo-lin; WU Chun-nuan; WANG Chen

Department of Pharmacy，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Tianjin Cancer Prevention and Therapy，Tianjin’s Clinical Research Center for Cancer，Tianjin 30060，China

关键词:

NCI-H520细胞; 左卡尼汀; 多西他赛; P21; P53

Keywords:

NCI-H520 cells; l-carnitine; docetaxel; P21; P53

分类号:

R969.2

DOI:

-

文献标志码:

A

摘要:

目的：探究左卡尼汀对多西他赛抑制肺癌细胞NCI-H520增殖的影响，并初步探索其机制。方法：实验将NCI-H520细胞分为阴性对照组，左卡尼汀组，多西他赛组以及联合用药组。四甲基偶氮唑蓝（MTT）法检测细胞增殖情况，流式细胞仪检测细胞凋亡和细胞周期，蛋白质免疫印迹法检测目标蛋白P21，P53，BAX和BCL-2的表达情况。结果：与不同单药组（左卡尼汀组和多西他赛组）相比，联合用药组对细胞增殖的抑制作用均增强，细胞增殖率分别由（95.5±3.97）%和（65.73±2.22）%下降到（54.4±1.67）%，P＜0.01，镜下细胞密度下降。联合用药使G1/G0期细胞分别由（67.21±6.0）%和（11.52±0.89）%下降到（3.98±0.42）%，P＜0.05。G2/M期细胞分别由（11.84±5.05）%和（54.91±2.38）%上升到（64.56±0.9）%，P＜0.05。周期相关蛋白P21，P53的表达量增加，且差异均具有统计学意义。所有实验组之间的细胞凋亡率和凋亡相关蛋白BAX，BCL-2的表达量没有明显差异。结论：24 h时，联合用药组中，左卡尼汀可能通过上调P21，P53的蛋白表达来增强细胞的G2/M期阻滞，进而增强多西他赛对NCI-H520细胞增殖的抑制作用。

Abstract:

Objective: To investigate the influences of l-carnitine on the inhibitory effects of docetaxel in NCI-H52O cells, and to explore its mechanism. Methods: NCI-H520 cells were divided into control group, L-carnitine group, docetaxel group and combination drugs group. MTT assay was used to detect the cell proliferation, flow cytometry was applied to determine cell apoptosis and cell cycle，and Western blot was performed to determine the expression of target protein- P21, P53, BAX and BCL-2. Results: Compared with the different single drug group（l-carnitine group and docetaxel group）, the combined drugs group enhanced the inhibition of cell proliferation, the cell proliferation rate decreased from (95.5±3.97)% and (65.73±2.22)% to (54.4±1.67)%, P＜0.01, and the cells density decreased under the microscope. The combination drugs decreased the cells in G0/G1 phase from (67.21±6.0)% and (11.52±0.89)% to (3.98±0.42)%, P＜0.05. And the cells in G2/M phase increased from (11.84±5.05)% and (54.91±2.38)% to (64.56±0.9)%, P＜0.05. The expression levels of cycle-related proteins P21 and P53 were up-regulated, and these changes were statistically different. There were no significant differences in the apoptosis rate and the expression of apoptosis-related proteins BAX and BCL-2 among all groups. Conclusion: In the combination drugs group, l-carnitine may enhance the G2/M phase arrest by up-regulating the expression of P21 and P53 proteins at 24 h, and thus enhance the inhibitory effects of docetaxel on NCI-H520 cell proliferation.

参考文献/References:

[1] Chung C. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics[J]. J Oncol Pharm Pract, 2016，22（3）：461
[2] Azarenko O，Smiyun G，Mah J， et al. Antiproliferative mechanism of action of the novel taxanecabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells[J]. Mol Cancer Ther，2014，13（8）：2092
[3] Schiller J H，Harrington D，Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med，2002，346（2）：92
[4] Peters S，Adjei A A，Gridelli C， et al. Metastatic non-small-cell lung cancer（NSCLC）：ESMO Clinical Practice Guidelines for diagnosis， treatment and follow-up[J].Ann Oncol，2012，23（Suppl 7）：vii56
[5] Curigliano G，Cardinale D，Suter T， et al. Cardiovascular toxicity induced by chemotherapy， targeted agents and radiotherapy： ESMO Clinical Practice Guidelines[J]. Ann Oncol，2012，23（Suppl 7）：vii155
[6] Agarwal A，Sengupta P，Durairajanayagam D. Role of L-carnitine in female infertility[J].ReprodBiol Endocrinol，2018，16（1）：5
[7] El-Ashmawy N E，Khalil R M.A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer[J]. Tumour Biol，2014，35（4）：2845
[8] 叶因涛，王晨，王冬，等. 左卡尼汀联合表柔比星对GLC-82细胞增殖及凋亡影响机制的探讨[J]. 中华肿瘤防治杂志，2013， 20（10）：744
[9] 郎娟娟，刘艳霞，钱兴运，等. 左卡尼汀联合多西他赛对GLC-82细胞增殖与凋亡影响研究[J]. 中华肿瘤防治杂志，2017，24（4）：223
[10] 郎娟娟，钱兴运，陶若琳，等.左卡尼汀联合氟尿嘧啶对MGC803细胞增殖及凋亡影响的研究[J].中国药学杂志，2016，51（24）：2102
[11] Jackson J G，Post S M，Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo[J]. J Pathol，2011，223（2）：127
[12] Vogelstein B，Lane D，Levine A J. Surfing the p53 network[J].Nature，2000，408（6810）：307
[13] Purvis J E，Karhohs K W，Mock C， et al. p53 dynamics control cell fate[J].Science，2012，336（687）：1440
[14] Lee E P，Muller W J. Oncogenes and tumor suppressor genes[J].Experientia，1996，52（1）：A64
[15] He G，Siddik Z H，Huang Z， et al. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities[J]. Oncogene，2005，24（18）：2929
[16] Abbas T，Dutta A. p21 in cancer： intricate networks and multiple activities[J]. Nat Rev Cancer，2009，9（6）：400
[17] Bizarro A，Ferreira I C，Sokovi■ M， et al. Cordycepsmilitaris （L.） Link Fruiting Body Reduces the Growth of a Non-Small Cell Lung Cancer Cell Line by Increasing Cellular Levels of p53 and p21[J].Molecules，2015，20（8）：13927
[18] Guterres F A，Martinez G R，Rocha M E， et al. Simvastatin rises reactive Oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway[J]. Exp Cell Res，2013，319（19）：2977
[19] Du W W，Yang W N，Liu E， et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2[J].Nucleic Acids Res，2016，44（6）：2846
[20] 李瑛，石廷章，焦顺昌，等. 多西他赛诱导HL60细胞凋亡的实验研究[J]. 肿瘤防治杂志，2005，12（24）：1854

相似文献/References:

备注/Memo

备注/Memo:

-

常用功能

更新日期/Last Update: 2018-09-30